Abstract: A fusion protein can include: a series of polypeptide domains starting from an N-terminus or C-terminus, the series of polypeptide domains comprising in order: an oligomerization domain having an oligomerization amino acid sequence that oligomerizes with other polypeptides having the oligomerization amino acid sequence; a first spacer domain having a first spacer amino acid sequence of at least 6 amino acids; an antigenic domain having an antigenic amino acid sequence of an antigen that is immunogenic, wherein the antigen is from one of: Domain III of an envelope glycoprotein of a flavivirus; hemagglutinin of a H5 influenza virus, or receptor binding domain of a SARS-COV-2 virus; a second spacer domain having a second spacer amino acid sequence of at least 6 amino acids; and optionally a purification tag having a purification amino acid sequence that binds with a purification substrate.

Abstract: A compound can include the structure of Formula 1, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center: R1 includes a hydrogen or a substituent; R2 includes a hydroxyl, hydroxyl-forming prodrug, or hydroxyl-leaving chemical moiety; R3 includes a halogen; and R4 includes a heterocycle. The compound can be an antiviral compound used in antiviral therapies.

Abstract: A compound comprising a structure of Compound 1, or prodrug thereof, salt thereof, or tautomer, polymorph, solvate, or combination thereof, can be used as an adjuvant in vaccines. The Compound 1 can be used in: methods of performing a vaccination; methods of agonizing a TLR 7 and/or TLR 8; and/or methods of activating an immune system.

Abstract: A compound can include the structure of Formula 1, derivative thereof, prodrug thereof, salt thereof, stereoisomer thereof, tautomer thereof, polymorph thereof, or solvate thereof, or having any chirality at any chiral center: R1 includes a hydrogen or a substituent; R2 includes a hydroxyl, hydroxyl-forming prodrug, or hydroxyl-leaving chemical moiety; R3 includes a halogen; and R4 includes a heterocycle. The compound can be an antiviral compound used in antiviral therapies.

Abstract: The various examples presented herein are directed to compounds of the Formula: wherein R1-R5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.

Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.

Abstract: The various examples presented herein are directed to compounds of the Formula: wherein R1-R5 are defined herein, and uses of such compounds to, among other things, inhibit an immune response in a subject.

Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR7 or TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae. Examples of the compounds can be reviewed in Table 1 and Table A1 for activates.